NorthWest Biotherapeutics Inc (NWBO)

[LearningEveryTrade]

All crossover's were on a "re-start" schedule for vaccination.
I don't call a "re-start schedule" a double does like you see it, but I get your point.

"All patients were allowed to receive DCVax-L following tumor progression/recurrence, as well as other approved treatments per local practice. All parties (investigators, patients and sponsor) remained blinded as to which treatment each patient had received prior to crossover. All patients who chose this option were given the active treatment on a re-start schedule with immunizations at Days 0, 10 and 20, and then months 2, 4 and 8, and every 6 months thereafter beginning with month 12, with Day 0 being the day of the first vaccination post progression. To date, DCVax-L has been shipped for 286 patients (86.4%) in the trial."
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6